All In Biotech

Free tool

FAERS Monitor: Tazorac

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020600 or its brand name (Tazorac, Tazarotene). Reports on generic versions are filed under their own applications.

Reports

945

Serious

382

40% of reports

Hospitalization

164

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective94
  • off label use74
  • pain52
  • headache51
  • erythema47
  • pruritus44
  • skin exfoliation42
  • rash41
  • psoriasis40
  • diarrhoea36
  • nausea34
  • acne33
  • pregnancy32
  • dry skin31
  • fatigue31

Reports by year received

View as table
YearReports
200411
200529
200612
200713
200817
20098
201043
201130
201275
201347
201424
201540
201688
201757
201868
201967
202037
202125
202240
202388
202446
202538
202642

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,214 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pregnancySignal3235.625.31,042
skin exfoliationSignal4211.18.2377
acneSignal339.76.9249
psoriasisSignal406.85.0194
dry skinSignal315.23.7101
erythemaSignal475.13.9152
pruritusSignal442.51.941
rashSignal412.11.623
pain521.91.421
off label use741.91.531
headache511.81.418
drug ineffective941.61.321
diarrhoea361.20.92
nausea341.00.70
fatigue310.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.